|
 |
|
|||||||
|
|||||||||
Diabetes 51:3077-3082, 2002
© 2002 by the American Diabetes Association, Inc.
C-Peptide Exerts Beneficial Effects on Myocardial Blood Flow and Function in Patients With Type 1 Diabetes
1 Section of Cardiology, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
2 Section of Clinical Physiology, Department of Surgical Sciences, Karolinska Hospital, Stockholm, Sweden
Myocardial dysfunction, perfusion abnormalities, and the extent to which these abnormalities may be reversed by C-peptide administration was assessed in type 1 diabetic patients. Eight patients were studied before and during a 0.84-mg/kg dipyridamole administration using a randomized double-blind crossover protocol with infusion of C-peptide (6 pmol · kg-1 · min-1) or saline during 60 min on two different days. Myocardial function was measured as peak myocardial velocity during systole (Vs) and early diastole (Vd) by pulsed tissue Doppler imaging. Myocardial contrast echocardiography was used for assessment of myocardial blood volume (SImax) and myocardial blood flow index (MBFI) calculated from the relation between trigger interval and signal intensity. Eight age-matched healthy volunteers served as control subjects. In the basal state, Vd (13.8 ± 0.6 vs. 15.6 ± 0.5 cm/s, P < 0.04) and SImax (6.6 ± 0.6 vs. 8.2 ± 0.6 a.u. P < 0.04) were reduced in patients compared with control subjects. Dipyridamole administration significantly increased indexes of myocardial function and blood flow to a similar extent in patients and control subjects. During C-peptide administration, Vs and Vd increased by 12% (P = 0.03), SImax increased from 6.6 ± 0.6 to 8.1 ± 0.7 a.u. (P < 0.02), and MBFI increased from 3.3 ± 0.4 to 5.3 ± 0.9 (P < 0.05). The results demonstrate that type 1 diabetic patients have impaired myocardial function and perfusion in the basal state that can be improved by short-term replacement of C-peptide.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S Moir, L Hanekom, Z-Y Fang, B Haluska, C Wong, M Burgess, and T H Marwick Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: a study of quantitative contrast echocardiography and strain rate imaging Heart, October 1, 2006; 92(10): 1414 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Polska, J. Kolodjaschna, F. Berisha, M. M. Malec, C. Simader, M. Bayerle-Eder, M. Roden, and L. Schmetterer C-Peptide does not affect ocular blood flow in patients with type 1 diabetes. Diabetes Care, September 1, 2006; 29(9): 2034 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T H Marwick Diabetic heart disease Heart, March 1, 2006; 92(3): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H von Bibra, A Hansen, V Dounis, T Bystedt, K Malmberg, and L Ryden Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes Heart, December 1, 2004; 90(12): 1483 - 1484. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Y. Fang, J. B. Prins, and T. H. Marwick Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications Endocr. Rev., August 1, 2004; 25(4): 543 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-L. Johansson, J. Sundell, K. Ekberg, C. Jonsson, M. Seppanen, O. Raitakari, M. Luotolahti, P. Nuutila, J. Wahren, and J. Knuuti C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E14 - E19. [Abstract] [Full Text]
|
|
|
|
|
|
B.-L. Johansson, J. Wahren, and J. Pernow C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E864 - E870. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |